This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Muscular Dystrophies
and you are
over 5
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine if GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping. Two doses of GSK2402968 and placebo will be used in this study.

Provided treatments

  • Drug: GSK2402968 3mg/kg/week
  • Drug: GSK2402968 6 mg/kg/week
  • Drug: Placebo to match GSK2402968 3 mg/kg/week
  • Drug: Placebo to match GSK2402968 6 mg/kg/week

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01462292. The sponsor of the trial is GlaxoSmithKline and it is looking for 51 volunteers for the current phase.
Official trial title:
An Exploratory Study to Assess Two Doses of GSK2402968 in the Treatment of Ambulant Boys With Duchenne Muscular Dystrophy